Sentences with phrase «kinase inhibitors in»

Dr. Kilian V. M. Huber received his doctorate in Medicinal and Pharmaceutical Chemistry from the Ludwig - Maximilians - Universität (LMU) in Munich working on the design and synthesis of natural product - inspired kinase inhibitors in the group Prof. Franz Bracher.

Novel drug therapies and novel indications of drug therapy, e.g. tyrosine kinase inhibitors in lung disease other than lung cancer, biological treatments for asthma, COPD, cystic fibrosis and interstitial lung disease.

Vorinostat interferes with the signaling transduction pathway of T - cell receptor and synergizes with phosphoinositide - 3 kinase inhibitors in cutaneous T - cell lymphoma

This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

Not exact matches

Pfizer (pfe) breast cancer treatment Ibrance burst onto the scene in early 2015 and proceeded to dominate in a new therapeutic arena called cyclin - dependent kinase (CDK) 4 and 6 inhibitors.

In contrast, HPV - inactive tumors often have mutations in the PIK3CA / PTEN / AKT pathway, indicating that AKT kinase inhibitors may be effective treatment options for these patients.&raquIn contrast, HPV - inactive tumors often have mutations in the PIK3CA / PTEN / AKT pathway, indicating that AKT kinase inhibitors may be effective treatment options for these patients.&raquin the PIK3CA / PTEN / AKT pathway, indicating that AKT kinase inhibitors may be effective treatment options for these patients.»

The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway).

Therefore, a novel therapeutic approach in inflammatory breast cancer could involve a combination of conventional chemotherapy with small - molecule inhibitors of the Cdk2 cell cycle kinase.

An approach often used in treating CML is to block the Bcr - Abl activity using tyrosine kinase inhibitors (TKIs).

And none of these kinase inhibitors have yet been rigorously tested in a head - to - head comparison with the protein therapies already on the market.

These results not only show promise on a new targeted therapy to treat this malignancy, as PI3K inhibitors are already used in the clinical practice, but also unravel a new function of the PI3K kinase in cancer biology through its role in promoting metastasis.

Imatinib is an inhibitor that blocks the ATP - binding site of the tyrosine kinase Abl in affected blood cells, thereby suppressing their overactivity.

These studies will investigate whether Src kinase inhibitors are best used in the adjuvant setting post-surgery or after chemotherapy to prevent the formation of local and distant disease recurrence.

One of the more intriguing findings in the study was that increasing histone crotonylation works synergistically with other known anti-HIV latency molecules, such as the protein kinase C agonist PEP005 and the HDAC inhibitor vorinostat.

However, advances in therapy have been made, notably the emergence of kinase inhibitors for patients whose disease relapsed, according to the study background.

Researchers found that genetically disrupting this pathway, or using the FDA - approved Src kinase inhibitor dasatinib, increases PUMA levels and decreases tumor progression and metastasis in mice by up to fivefold.

In the study, the authors suggest that using Src kinase inhibitors may be more effectively used as adjuvant therapies to block αvβ3 signaling and prevent disease spread.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

Vemurafenib joins other multi-targeted kinase inhibitors (MKIs)(sorafenib, lenvatinib) shown to be effective in this patient population; in spite of responses to these drugs, the responses are temporary and additional treatment options are needed.

DDRs inhibition with a tyrosine kinase inhibitor appears to insulate the brain via blood - brain barrier repair, which prevents harmful immune cells that circulate in the body from getting into the brain where they can indiscriminately attack and kill healthy and sick neurons, like those that have been unable to perform autophagy to «take out their trash,» says Moussa.

One option is an MEK inhibitor, which inhibits the mitogen - activated protein kinase enzymes used to therapeutically affect the MAPK pathway that is often overactive in cancers.

In experiments using enzyme inhibitors, the possibility that cinnamtannin B - 1 enhanced mobilization through the use of activation of enzymes such as PI3 kinase near the cell membrane was shown.

Pao was involved in studies of EGFR tyrosine - kinase inhibitors while at MSKCC, where he trained in medical oncology.

The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC - UNC), in partnership with the DiscoverX Corporation, has reached the milestone halfway point in its development of the Kinase Chemogenomic Set, a potent group of inhibitors which allow deeper exploration of the human kinome, a family of enzymes critical to understanding human disease and developing new therapies.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

THE STUDIES A trilogy of papers published in the September 28 issue of Nature examine the role of a protein — cyclin - dependent kinase inhibitor p16INK4a — in aging, healing, and cancer.

«Through our collaboration with DiscoverX, we screened a large set of compounds that we call Published Kinase Inhibitor Set 2, and these results allowed us to reach the halfway point in constructing the KCGS» said David Drewry, a research associate professor at the UNC Eshelman School of Pharmacy and SGC - UNC principal investigator who is leading the project to develop the Kinase Chemogenomic Set.

The drug is a multi - kinase inhibitor (MKI)-- meaning it targets the specific enzymes that are required for growth in DTC.

In a proof - of - concept study, Fourches and Ash looked at the ERK2 kinase — an enzyme associated with several types of cancer — and a group of 87 known ERK2 inhibitors, ranging from very active to inactive.

This visual abstract depicts how Wei et al. utilize single - cell phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

In practice, this means that when medicinal chemists discover a promising kinase inhibitor that exists as two interchanging arrangements, they actually have two different inhibitors.

This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available.

But whether p38 MAP kinase inhibitors could be used to treat arthritis in humans is unclear, she says.

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life - threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

Rho - kinase inhibitor Y - 27632 and hypoxia synergistically enhance chondrocytic phenotype and change the S100 protein profile in human chondrosarcoma cells

We used the janus kinase (JAK) inhibitor baricitinib with IFN - blocking activity in vitro, to ameliorate disease.

Kinases are also druggable targets, as seen by the success of kinase - inhibitors in earning FDA approval (including, for example, crizotinib against ALK - fusion and erlotinib against EGFR).

Rho - kinase inhibitor Y - 27632 increases cellular proliferation and migration in human foreskin fibroblast cells

These data reveal that the tissue damage present in this SIRS model is reflected, in part, by breaks in the vasculature due to endothelial cell necroptosis and thereby predict that RIPK1 kinase inhibitors may provide clinical benefit to shock and / or sepsis patients.

This thesis primarily investigates the effects of mechanical cyclic stretching, a 5 % low oxygen atmosphere and the Rho - kinase inhibitor, Y - 27632, on protein responses in chondrocytic human chondrosarcoma (HCS - 2 / 8) cells.

In 2005, Cagan's team created a general fly model of a human thyroid tumor caused by mutations in the Ret receptor tyrosine kinase gene, then screened a panel of drugs including a kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005In 2005, Cagan's team created a general fly model of a human thyroid tumor caused by mutations in the Ret receptor tyrosine kinase gene, then screened a panel of drugs including a kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005in the Ret receptor tyrosine kinase gene, then screened a panel of drugs including a kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005).

PHIb Trial of Fulvestrant, Palbociclib (CDK4 / 6 inhibitor) and Erdafitinib (JNJ - 42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER + / HER2 - / FGFR - amplified Metastatic Breast Caninhibitor) and Erdafitinib (JNJ - 42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER + / HER2 - / FGFR - amplified Metastatic Breast CanInhibitor) in ER + / HER2 - / FGFR - amplified Metastatic Breast Cancer (MBC)

Clough BH, Zeitouni S, Krause U, et al., Rapid Osteogenic Enhancement of Stem Cells in Human Bone Marrow Using a Glycogen ‐ Synthease ‐ Kinase ‐ 3 ‐ Beta Inhibitor Improves Osteogenic Efficacy In Vitro and In Vivin Human Bone Marrow Using a Glycogen ‐ Synthease ‐ Kinase ‐ 3 ‐ Beta Inhibitor Improves Osteogenic Efficacy In Vitro and In VivIn Vitro and In VivIn Vivo.

In the late 1990s, STI - 571 (imatinib, Gleevec / Glivec) was identified by the pharmaceutical company Novartis (then known as Ciba Geigy) in high - throughput screens for tyrosine kinase inhibitorIn the late 1990s, STI - 571 (imatinib, Gleevec / Glivec) was identified by the pharmaceutical company Novartis (then known as Ciba Geigy) in high - throughput screens for tyrosine kinase inhibitorin high - throughput screens for tyrosine kinase inhibitors.

This lab, in collaboration with the lab of Ruben Shaw at the Salk Institute, recently identified SBI - 0206965, the first potent and selective small molecule inhibitor of ULK1, a serine / threonine kinase that is a critical regulator of autophagy.

A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine or low - dose cytarabine is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.

Glennie et al 134 have shown that T cells stimulated in co-cultures with MSC exhibit an extensive inhibition of cyclin D2 and upregulation of the cyclin dependent kinase inhibitor p27kip1.